Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Astellas to Acquire US Upstart Propella for Prostate Cancer Drug
November 17, 2023
- Japanese Pricing Rules Don’t Fully Capture Value of New Modalities, “No” to CEA Expansion: Janssen Exec
November 17, 2023
- Novo Nordisk Curbs Insulin Shipments Due to Surge in Demand for Diabetes Meds
November 17, 2023
- Astellas, University of Tsukuba Tie Up in Drug Discovery and Startup Incubation
November 17, 2023
- Xocova, Dayvigo Again Winner in Sept Rep Promotion Rankings for GPs, HPs: Intage
November 17, 2023
- AbbVie Japan Files Rinvoq 30 mg Regimen for Age 12-Plus Atopic Dermatitis Patients
November 16, 2023
- Change in Dynamics? Suzuken Emerges as No. 2 among Big 4 Japan Wholesalers
November 15, 2023
- Kao, NANO MRNA to Initiate Joint Research for mRNA Drug Discovery
November 15, 2023
- iPark Institute Inks Collaboration Pact with South Korean Government
November 14, 2023
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
- Taisho Hits “Reset” Button for Pharma Biz with 600-Plus Job Cuts
November 14, 2023
- Ajinomoto to Acquire US Gene Therapy CDMO for US$554 Million
November 14, 2023
- UCB Seeks Hidradenitis Suppurativa Nod for Bimzelx in Japan
November 13, 2023
- Otsuka Files NDA for Lupus Nephritis Drug in Japan
November 13, 2023
- Takeda Scores 1st US Nod for Ultra-Rare Blood Clotting Disorder
November 13, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- Takeda Gets US Clearance for Hutchmed’s Colorectal Cancer Drug
November 10, 2023
- Middle East Unrest Threatens Supply of Kaken’s Burn Eschar Remover
November 9, 2023
- Mitsubishi Licenses Neuropsychiatric Drug to Dutch Startup Kynexis
November 9, 2023
- Japan Ethical Drug Sales Up 6.8% in September: Crecon
November 9, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…